XTANDI™ SOFT CAPSULES 40MG Singapore - English - HSA (Health Sciences Authority)

xtandi™ soft capsules 40mg

astellas pharma singapore pte. ltd. - enzalutamide - capsule, liquid filled - enzalutamide 40.0 mg

XTANDI 40 MG TABLETS Israel - English - Ministry of Health

xtandi 40 mg tablets

astellas pharma international b.v., israel - enzalutamide - film coated tablets - enzalutamide 40 mg - enzalutamide - xtandi is indicated for:• the treatment of adult men with high-risk non-metastatic castration-resistant prostate cancer (crpc).• the treatment of adult men with metastatic crpc who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicated.• the treatment of adult men with metastatic crpc whose disease has progressed on or after docetaxel therapy.•the treatment of adult men with metastatic hormone-sensitive prostate cancer (mhspc) in combination with androgen deprivation therapy

Enzalutamide Sandoz 40 mg film-coated tablets Malta - English - Medicines Authority

enzalutamide sandoz 40 mg film-coated tablets

sandoz pharmaceuticals d.d. verovškova ulica 57, si-1000 ljubljana, slovenia - film-coated tablet - enzalutamide 40 mg - endocrine therapy

Enzalutamide Sandoz 80 mg film-coated tablets Malta - English - Medicines Authority

enzalutamide sandoz 80 mg film-coated tablets

sandoz pharmaceuticals d.d. verovškova ulica 57, si-1000 ljubljana, slovenia - film-coated tablet - enzalutamide 80 mg - endocrine therapy

Xtandi European Union - English - EMA (European Medicines Agency)

xtandi

astellas pharma europe b.v. - enzalutamide - prostatic neoplasms - endocrine therapy - xtandi is indicated for:the treatment of adult men with metastatic hormone-sensitive prostate cancer (mhspc) in combination with androgen deprivation therapy (see section 5.1).the treatment of adult men with high-risk non-metastatic castration-resistant prostate cancer (crpc) (see section 5.1).the treatment of adult men with metastatic crpc who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicated (see section 5.1).the treatment of adult men with metastatic crpc whose disease has progressed on or after docetaxel therapy.

Enzalutamide Adalvo 40 mg soft capsules Malta - English - Medicines Authority

enzalutamide adalvo 40 mg soft capsules

adalvo limited malta life sciences park, building 1, level 4 sir temi zammit san gwann industrial est, sgn 3000 san gwann, malta - lenalidomide - soft capsule - enzalutamide 40 mg - endocrine therapy

XTANDI 80 MG TABLETS Israel - English - Ministry of Health

xtandi 80 mg tablets

astellas pharma international b.v., israel - enzalutamide - film coated tablets - enzalutamide 80 mg - enzalutamide - xtandi is indicated for:• the treatment of adult men with high-risk non-metastatic castration-resistant prostate cancer (crpc).• the treatment of adult men with metastatic crpc who are asymptomatic or mildly symptomatic after failure ofandrogen deprivation therapy in whom chemotherapy is not yet clinically indicated.• the treatment of adult men with metastatic crpc whose disease has progressed on or after docetaxeltherapy.• the treatment of adult men with metastatic hormone-sensitive prostate cancer (mhspc) in combination with androgen deprivation therapy